Analyst Joel Fishbein of BTIG maintained a Buy rating on Imperva Inc (NYSE:IMPV) with a price target of $55, marking a 12% increase from current levels. The company has recently consulted with investment banks for “strategic options” and  the analyst believes that today’s active M&A environment bodes well for asset sales for Imperva. Fishbein believes that a sale is likely with buyers being able to “benefit from Imperva’s strong portfolio and leadership position in the space.” According to TipRanks, the analyst has a success rate of 65% with an average return of 14.2% per recommendation.